Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical tacrolimus for breast cancer-related lymphedema
2023-503644-13-00Phase 3Authorised
- Sponsor
- University Hospital Odense
- Start
- Sep 2024
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer-related lymphedema (BCRL) comparing Topical tacrolimus with Topical placebo (2 arms). Primary endpoint: Change in lymphedema volume. Planned start Sep 2024; status: authorised.
02
Drugs
tacrolimus
03
Conditions
breast cancer-related lymphedema (BCRL)
Beyond the preview
Go deeper on 2023-503644-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503644-13-00.